Most Read Articles
Pearl Toh, 02 Sep 2020
Proton beam radiotherapy (PBT) was noninferior to radiofrequency ablation (RFA) for local progression-free survival (LPFS) in patients with recurrent hepatocellular carcinoma (rHCC), in addition to showing a tolerable safety profile, according to the APROH trial presented during the 2020 digital ILC.
Elaine Soliven, 11 Sep 2020
Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.

Besifovir dipivoxil maleate delivers long-term safety, efficacy in CHB

22 Aug 2020

Treatment with besifovir dipivoxil maleate (BSV) is effective and safe for long-term use in treatment-naïve and tenofovir disoproxil fumarate (TDF)-experienced patients with chronic hepatitis B (CHB), results of a phase III trial have shown.

CHB patients continued the open-label BSV study after 48 weeks of a double-blind comparison between BSV and TDF treatments. The investigators examined the antiviral efficacy and drug safety up to 144 weeks for the BSV-BSV and TDF-BSV groups.

A total of 197 patients were included in the trial, among whom 170 entered the second-year open-label phase extensional study, 158 entered the third-year open-label phase, and 153 completed the 144-week follow-up. The primary endpoint of virological response (hepatitis B virus DNA <69 IU/mL) was achieved by 87.7 percent and 92.1 percent of patients in the BSV-BSV and TDF-BSV groups, respectively, over the 144-week period (p=0.36).

No between-group difference was noted in the rates of ALT normalization and HBeAg seroconversion. There were also no drug-resistant mutations to BSV observed. Bone mineral density and renal function were well preserved in the BSV-BSV group and were significantly improved after switching therapy in the TDF-BSV group.

“BSV treatment maintained antiviral efficacy over 144-week period without any viral resistance,” the investigators said. “BSV administration was safe, well-tolerated, and effective for treatment-naïve patients with CHB as well as those who switched from TDF to BSV treatment.”

CHB remains a public health problem across the globe despite the presence of vaccines and antivirals. [J Hepatol 2017;67:370-398; Lancet 2015;386:1546-1555]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 02 Sep 2020
Proton beam radiotherapy (PBT) was noninferior to radiofrequency ablation (RFA) for local progression-free survival (LPFS) in patients with recurrent hepatocellular carcinoma (rHCC), in addition to showing a tolerable safety profile, according to the APROH trial presented during the 2020 digital ILC.
Elaine Soliven, 11 Sep 2020
Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.